Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
R&D channel feed
Novartis is sending 500 jobs to the scrap heap while adding 350 ‘high-tech’ positions for growth
9 years ago
Pharma
#ASCO17 highlights: Roche ushers early-stage bispecific into view; Agios, Celgene unveil more AG-221 data; Plenty more coming at ASCO
9 years ago
Shire’s multibillion-dollar gamble on lanadelumab pays off with stellar PhIII data, quick marketing application
9 years ago
#ASCO17: Epizyme will hunt a quick OK for tazemetostat, despite disappointing analysts with new data
9 years ago
#ASCO17: Incyte gets a boost from a series of positive data snapshots for its epacadostat/Keytruda combo
9 years ago
Syndax shares soar as lead drug clears a mid-stage cancer drug study hurdle
9 years ago
Novartis steps in to help seed a Michigan spinout’s move into the clinic with new eye drug
9 years ago
FDA forces Concert Pharma to hit the brakes on a mid-stage study so it can review tox studies
9 years ago
Pharma
J&J pitches its top 11 drugs in the pipeline — with a peak sales promise of $1B-plus
9 years ago
Editas loses its lead in the biotech race to launch the first CRISPR/Cas9 human study
9 years ago
Ionis says it gathered promising PhIII data for a top rare disease drug, but serious safety questions remain
9 years ago
Biogen shutters a biotech shop in the UK as it continues to prune R&D
9 years ago
Pharma
Playing catch-up, Eli Lilly is hustling positive PhIII CGRP migraine data to the FDA as late-stage rivalry heats up
9 years ago
Ardelyx rolls out positive PhIII IBS-C data on tenapanor as rivals prep for a showdown, but shares crater
9 years ago
AstraZeneca’s shares spike on a surprise coup in PhIII lung cancer data
9 years ago
Regulators order AB Science to halt trial work on PhIII ALS drug, demanding proof it's cleaned up
9 years ago
Pharma
Array shares surge as second chapter of its PhIII cancer combo story ends on an upbeat note
9 years ago
AstraZeneca’s PhIII bid on asthma drug tralokinumab flops, and that’s no surprise
9 years ago
In a stunning setback, Roche says its top cancer drug Tecentriq failed a key PhIII study
9 years ago
PhRMA drums out 22 members who didn’t make the cut as major league R&D players
9 years ago
Pharma
Synergy Pharma preps step 2 for Trulance as positive PhIII IBS-C data squares off against Ironwood and Ardelyx
9 years ago
Recro Pharma tees up an NDA for its COX-2 pain drug following positive PhIII program
9 years ago
One of Kite Pharma’s CAR-T patients died from cerebral edema, triggering a safety alarm
9 years ago
OncoMed racks up three straight clinical disasters as lead drug implodes
9 years ago
First page
Previous page
302
303
304
305
306
307
308
Next page
Last page